POS0052 FIVE-YEAR FOLLOW-UP OF A 2-YEAR MRI TREAT-TO-TARGET STRATEGY ON RADIOGRAPHIC DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION - THE IMAGINE-MORE STUDY
Authors: S. Møller-Bisgaard, K. Hørslev-Petersen, L. Midtbøll Ørnbjerg, B. Ejbjerg, M. L. Hetland, J. Møllenbach Møller, R. Christensen, S. M. Nielsen, D. Glinatsi, M. Boesen, K. Stengaard-Pedersen, O. Madsen, B. Jensen, J. A. Villadsen, E. M. Hauge, O. Hendricks, H. M. Lindegaard, N. Steen Krogh, A. G. Jurik, H. Thomsen, M. Østergaard
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Radiographic joint damage progresses in 20-30% of rheumatoid arthritis (RA) patients despite fulfilling clinical remission criteria [1]. Osteitis assessed on MRI predicts subsequent bone damage progression [2]. Therefore, targeting absence of osteitis combined with clinical remission may improve long-term radiographic outcomes. <h3>Objectives</h3> To investigate whether a 2-year MRI treat-to-target (MRI T2T) strategy targeting absence of osteitis combined with clinical remission, compared to a conventional T2T strategy targeting clinical remission only, could reduce radiographic joint damage progression over 5 years in RA patients. <h3>Methods</h3> IMAGINE-more was designed as a three-year observational extension study of the 2-year IMAGINE-RA randomized clinical trial [3]. IMAGINE-RA included 200 RA patients in clinical remission (DAS28-CRP&lt;3.2 and no swollen joints), with erosive disease (bone erosion on conventional radiography), and treated with csDMARDs. The objective was to investigate whether an MRI T2T strategy targeting absence of osteitis combined with clinical remission (DAS28-CRP≤3.2 and no swollen joints) as compared to a conventional T2T strategy, targeting clinical remission only, could improve remission rates and prevent radiographic joint damage progression. If treatment target was not met, treatment was intensified stepwise starting with increment in csDMARDs and subsequently adding biologics. Participants in the IMAGINE-more study were managed in routine clinical practice in outpatient clinics. Clinical examinations and radiographs of hands and feet (also obtained at baseline, year 1 and 2 in IMAGINE-RA) were done year 3, 4 and 5. The primary endpoint was the proportion of patients with no radiographic progression (increase in total van der Heijde-modified Sharp score (vdHSS) ≤0) from baseline to year 5. Secondary endpoints were 0-5 years changes in total vdHSS, vdHSS erosion and joint space narrowing (JSN) scores. Dichotomous endpoints were estimated by logistic regression, while median differences were calculated for the continuous outcome measures. <h3>Results</h3> Informed consent to participation in IMAGINE-more was obtained from 131 patients (59 from the original MRI T2T group). Of these, 14 patients (24%) in the MRI T2T group and 19 patients (26%) in the conventional T2T group had no radiographic progression from baseline to year 5 (OR 0.70 [0.28 to 1.71]). As illustrated in the Table 1 and Figure 1, the median progression in total vdHSS from baseline to 5 years was low, with no differences between treatment groups. <h3>Conclusion</h3> A 2-year combined MRI T2T and clinical T2T strategy, compared with a conventional clinical T2T strategy alone, did not result in reduced radiographic progression in the long term over 5 years in RA patients with erosive disease in clinical remission. <h3>References</h3> [1]Lillegraven et al. Ann Rheum Dis 2012 [2]Brown et al. Arthritis Rheum 2008 [3]Møller-Bisgaard et al. JAMA 2019 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Signe Møller-Bisgaard Grant/research support from: Study support from AbbVie, Kim Hørslev-Petersen: None declared, Lykke Midtbøll Ørnbjerg: None declared, Bo Ejbjerg: None declared, Merete Lund Hetland: None declared, Jakob Møllenbach Møller: None declared, Robin Christensen: None declared, Sabrina Mai Nielsen: None declared, Daniel Glinatsi: None declared, Mikael Boesen Shareholder of: Minority shareholder in Image Analysis Group LTD, London UK, Speakers bureau: AbbVie, Celgene, Eli Lilly, Image Analysis Group, Novartis, Pfizer, UCB and Esaote, Paid instructor for: Novartis and Eli Lilly, Consultant of: Novartis, Grant/research support from: AbbVie, Celgene, Novo Nordisk and Novartis, Kristian Stengaard-Pedersen Consultant of: Pfizer, AbbVie, Grant/research support from: Roche, Pfizer, AbbVie and Medoc., Ole Madsen: None declared, Bente Jensen: None declared, Jan Alexander Villadsen: None declared, Ellen Margrethe Hauge Shareholder of: Novartis, AbbVie, Sanofi, Sobi, Grant/research support from: esearch funding to Aarhus University Hospital from Novo Nordic Foundation, Danish Rheumatism Association, Danish Regions Medicine Grants, Roche, Novartis, AbbVie, Oliver Hendricks Speakers bureau: Pfizer, Lilly, Novartis, Hanne Merete Lindegaard: None declared, Niels Steen Krogh: None declared, Anne Grethe Jurik: None declared, Henrik Thomsen: None declared, Mikkel Østergaard Speakers bureau: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, MEDAC, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Grant/research support from: Abbvie, BMS, Merck, Novartis and UCB.